To further evaluate whether targeting GH action could serve as a therapeutic strategy, we confirmed GHR expression in NSCLC cells and examined their response in vitro to GH stimulation and inhibition by pegvisomant, an FDA-approved GHRA for acromegaly [40,41,42,43]. This evidence concerns the gene GH1 and acromegaly.